FDA Grants Priority Review To Roche Rituximab In Ped Blood Vessel Disorders

PEPRS STUDY IS FIRST GLOBAL TRIAL OF RITUXAN IN PEDIATRIC PATIENTS WITH GPA OR MPA

* RITUXAN IN COMBINATION WITH GLUCOCORTICOIDS IS ONLY FDA-APPROVED THERAPY FOR ADULTS WITH THESE TWO RARE FORMS OF VASCULITIS

* IF APPROVED, THIS WOULD BE FIRST PEDIATRIC INDICATION FOR RITUXAN

https://www.reuters.com/article/brief-fda-grants-priority-review-to-roch/brief-fda-grants-priority-review-to-roches-rituximab-in-children-with-blood-vessel-disorders-idUSASB01Q0O